Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Car-NTIMP3
- Development stage
- Preclinical
- Lead developer
- Università degli Studi di Roma Tor Vergata
- Modality
- Peptides
- Administration
- Intravenous
01
Overview
Car-NTIMP3 (also known as G3C12-NTIMP3) is a synthetic peptide conjugate designed for the treatment of diabetic nephropathy. It consists of the N-terminal domain of human tissue inhibitor of metalloproteinases 3 (TIMP3) conjugated to G3C12, a carrier peptide that selectively targets galectin-3 in the kidney. TIMP3 is an extracellular matrix-bound protein that physiologically inhibits metalloproteinases, particularly A Disintegrin and Metalloproteinase 17 (ADAM17) and matrix metalloproteinases (MMPs) such as MMP2 and MMP9. In diabetic nephropathy, loss of TIMP3 leads to increased ADAM17 and MMP activity, promoting inflammation, oxidative stress, and renal fibrosis. By delivering the active N-terminal domain of TIMP3 specifically to the kidney, Car-NTIMP3 restores TIMP3 inhibitory activity, reduces albuminuria, decreases extracellular matrix deposition, and ameliorates glomerular lesions and podocyte injury.
- Other names
- Car-NTIMP3 peptideCar-NTIMP-3 peptideCar-NTIMP 3 peptideG3C12-NTIMP3G-3C12-NTIMP3G 3C12-NTIMP3G3C12-NTIMP3 peptideG-3C12-NTIMP3 peptideG 3C12-NTIMP3 peptide
Beyond the preview
Go deeper on Car-NTIMP3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Car-NTIMP3.